180N - Kystsamarbeidet

Green top banner with triangle logo and the text 180N Norwegian nuclear medicine consortium

About 180N

Improved diagnostics and treatment through a state-of-the-art multi-center nuclear medicine approach: Applications in cancer and dementia

The overall objective of the project is to facilitate multi-center clinical nuclear medicine research by implementation and development of novel methodology and analyses in the diagnosis, follow up and treatment settings, to bring this field beyond state of the art for the betterment of patients across Norway. 

Hybrid PET/MRI will have a central role in this project, and therefor the focus is on patient groups where this modality has shown promising potential; In detection and characterization of cancer, as well as suspected dementia, for guiding treatment strategies in cancer, including implementation of multimodal data to guide latest technology within radiation, radionuclide and proton therapy and navigated neurosurgery, and to develop novel or improved, robust and clinically relevant image analysis tools. 

The multi-center data collection is coordinated from Trondheim, while patient inclusion and data collection are distributed across the partner sites in Tromsø, Trondheim, Bergen and Stavanger. In this project, hybrid imaging will merge nuclear medicine and radiological specialties to foster transdisciplinary collaborations at an expert level under international collaboration and supervision. The molecular and physiological data obtained with the unique combination of simultaneous PET/MRI will create the basis for new and improved understanding of disease pathophysiology, a steppingstone to develop new patient stratification and personalized treatment schemes.

WP1: Prostate Cancer

1 in 8 men will have prostate cancer in their lives. Molecular imaging may offer huge benefits in all stages of the diagnostic work-up, and PET imaging using the tracer prostate specific membrane antigen (PSMA) has shown promising results.

This WP aims to establish nation-wide protocols for PSMA-PET (in combination with hybrid MRI or CT) to evaluate the diagnostic accuracy for staging of high-risk prostate cancer and detection of recurrent disease. Furthermore, we will evaluate the benefit of longitudinal PSMA-PET to evaluate treatment response in castration resistant metastatic disease.

All studies will be performed with strict inclusion criteria in a prospective, multi-center design, where patients will be recruited and imaged at all partner hospitals.

Finally, this WP will pilot the feasibility of PSMA PET/MRI to guide focal treatment with state of the art interventions, such as proton beam therapy and PSMA based radionuclide therapy. 

WP2: Diagnostic assessment of amino acid PET/MRI in the evaluation of glioma and brain metastases

MRI is used in clinical routine for diagnosing brain tumors, but has limitations in identifying tumor grade, true tumor extension and differentiating viable tumor tissue from treatment induced changes and recurrences.

Many brain tumors express increased levels of amino acid transport, which can be imaged with a PET scanner using amino acid radiotracers. Using both MRI and PET will likely improve brain tumor diagnostics, resection, tissue sampling, treatment planning and therapy response assessment significantly.

In this study, combined PET/MRI and three of the most promising amino acid tracers (11C-MET, 18F-FET and 18F-FACBC) will be evaluated, with the aim to improve diagnostic accuracy in cerebral gliomas and brain metastases, at primary diagnosis and follow-up.

Multiparametric PET/MRI of a patient with primary glioma grade IV (glioblastoma). From left to right; 18F-FACBC PET, MRI T1 pre-contrast, MRI T1 post-contrast, MRI T2, MRI FLAIR, Fused 18F-FACBC PET/MRI, MRI Diffusion-weighted image, MRI ADC map, MRI perfusion-weighted image, MRI relative CBV map, and MRI spectroscopy.Caption

 

WP3: 

WP4: 

In WP4 we will establish the clinical workflow for PET- and MRI-based radiotherapy. We will acquire PET and MR images prior to and during radiotherapy and develop new concepts for image-based biologically adaptive radiotherapy, both based on state-of-the-art photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway.

Our aim is to contribute towards further developments of personalised high-precision radiotherapy resulting in improved outcome, reduced side-effects and better quality of life for cancer patients.

WP5: 

In the machine learning work package, we aim to develop and validate new methods that exploit the quantitative nature of the PET and MR images. We will develop a pipeline for pre-processing and quality assurance of the acquired images, as well as a toolbox with machine learning algorithms focusing on region classification and detection of change over time. These methods will be applied to answer open clinical questions in cancer and dementia.

WP Leaders

Tone Bathen, Professor, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU.

Torgrim Tandstad, Associate Professor, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Dept. of Oncology, St. Olavs University Hospital.

Live Eikenes, Associate professor Live Eikenes, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU.

Anna Karlberg, Medical Physicist, Department of Radiology and Nuclear Medicine, St. Olavs Hospital.

Asta Håberg, Professor, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU.

Geir Bråthen, Head of Neuroclinic, St. Olavs University Hospital and Associate Professor, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU.

Kathrine Røe Redalen, Associate Professor, Department of Physics, Faculty of Natural Sciences, NTNU.

Mirjam D. Kaminka Alsaker, Senior consultant Oncologist, Department of Radiotherapy, The Cancer Clinic St.Olavs University Hospital, and Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU.

Pål Erik Goa, Associate Professor, Department of Physics, Faculty of Natural Sciences, NTNU.

Mattijs Elschott, Researcher, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU.

Steering committee

Pål Romundstad (Professor, Vice Dean of Research, Department of public health and nursing, Faculty of Medicine and Health Sciences, NTNU)

Edmund Søvik (Head of Clinic, Department of Image Diagnostics and Nuclear Medicine, St. Olavs Hospital)

Einar Bugge (Director for quality improvement and development, Center for quality improvement and development, UNN)

Johanna Sollid (Vice Dean of Research, Faculty of Health Sciences, UiT)

Anne Marit Blokhus (Professor, Vice Dean of Research and Education, mat.nat., UiB)

Aslak Aslaksen (Professor, Department of Global Public Health and Primary Care, UiB)

Advisory Board

Toril Hernes (Professor, Pro-rektor for Innovasjon, NTNU)

Tom Anders Stenbro (Distriktssjef Kreftforeningen Trøndelag og Møre og Romsdal)

Wouter van Elmpt (Program Manager Innovation Team i MAASTRO Clinic, Maastricht, The Netherlands and Professor at the University of Maastricht)

Anette Storstein (Chairman Hjernerådet, MD, PhD, Department of Neurology, Haukeland University Hospital)

Bernhard Sattler (Head Medical Physics Nuclear Medicine, Associate Professor of Medical Engineering, University Hospital Leipzig)

Mona-Elisabeth Revheim (MD, Associate Professor, Oslo University Hospital and UiO)

180oN travel grants

The following travel grants can be applied for: 

A) Research stays abroad or within Norway for project participants

Apply for research stay grant

B) Incoming guest researchers

Apply for guest researcher grant

For both of these categories the project coordinators of 180°N will act as committee and award the applicants according to the evaluation criteria. Applications are accepted twice per year (15 February and 15 September). Decisions will be communicated directly to the applicants on 1 March and 1 October.

A. Research stays abroad or within Norway for project participants

Research stays abroad or within Norway for project participants Members of 180 °N can apply for a travel grant for research stays abroad or within Norway if the application provides a clear explanation on why and how the research stay will benefit the current project and 180°N.

The purpose of this stimulus should be to learn and transfer methods or techniques relevant for the work package, the project or the consortium as a whole. We emphasize that these research stays should create stronger professional relationships between the host, the envoyée and 180 °N. This could result in joint publications, EU applications, multi centre trials, etc. The grant will typically cover travel and accommodation costs. Diet costs are not covered on top of the sum provided. Other costs may be covered if the need for those are clearly documented (e.g. visa application) but is within the maximum funding amount for the specific time period. It can be applied for a research stay duration of 1 to 6 months. After the completion of the research term the applicant is required to present findings and experiences during the annual research conference. In addition, a two-page report + 2-3 photos will be required and published on the collaborative project web page.

The application must include the following:

  • Project plan, including any planned joint publications
  • An explanation of why and how the visit will benefit the work package and the 180°N project
  • An invitation from the host institution
  • Budget plan

We offer the following grants:

  • Research stays of one month, NOK 30 000 (including travel)
  • Research stays of two months, NOK 48 000 (including travel)
  • Research stays of three months or longer, NOK 60 000 (including travel)

B. Incoming guest researchers

The 180°N network can support incoming researchers to partner institutions if the application provides a clear explanation on why and how the research stay will benefit the current project and 180 °N. The purpose of this stimulus should be to learn and methods or techniques relevant for the work package, the project or the consortium as a whole. The incoming guest researcher should be beneficial to the whole work package or project he/she is associated with and should create stronger professional relationships. This could be beneficial towards e.g. joint publications, EU applications, multi centre trials, etc. The grant will typically cover travel and accommodation costs. We assume that the visiting partner continues to be paid by institution where he/she is employed. Other costs may be covered if the need for those are clearly documented (e.g. visa application) but is within the maximum funding amount for the specific time period. It can be applied for an incoming researcher for a duration of 1 to 6 months. A two-page report + 2-3 photos will be required and published on the collaborative and local project web page. 

The application must include the following:

  • Project plan, including any planned joint publications
  • An explanation of why and how the visitor will benefit to the work package and the 180°N project
  • An invitation from the host institution and agreement with employer of partnering institutioN
  • Plan for guest lectures or guest seminars
  • Budget plan

We offer the following grants:

  • Research stays up to one month, NOK 35 000 (including travel)
  • Research stays of two months, NOK 50 000 (including travel)
  • Research stays of three months or longer, NOK 60 000 (including travel)

Travel grants

Travel grants

Research stays abroad or within Norway for project participants:


Incoming guest researchers:


Deadline: 15. September 2020

For more information, klikk on the Travel Grants tab.

Funders

Funders

Partners

Partners